Cytokine secretion pattern in treatment of lymphocytes of multiple sclerosis patients with fumaric acid esters

Immunological Investigations

Volumn 40, Issue 6, 2011, Pages 581-596

  Zoghi, Samaneh ^a   Amirghofran, Zahra ^a,b,c   Nikseresht, Alireza ^b,d   Ashjazadeh, Nahid ^d   Kamali Sarvestani, Eskandar ^a,b   Rezaei, Nahid ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Fumaric acid esters; Multiple sclerosis

Indexed keywords

CD4 ANTIGEN; DIMETHYLFUMARATE; FUMARIC ACID ETHYL ESTER; GAMMA INTERFERON; INTERLEUKIN 4; METHYLHYDROGEN FUMARATE; MYELIN BASIC PROTEIN; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL STIMULATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOCYTE; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL SURVIVAL; CYTOKINES; FEMALE; FUMARATES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MALEATES; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PHYTOHEMAGGLUTININS; TH1 CELLS; TH2 CELLS; YOUNG ADULT;

EID: 79959580759     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2011.569626     Document Type: Article

References (25)

1. Asadullah, K., Schmid, H., Friedrich, M., Randow, F., Volk, H. D., Sterry, W., et al. (1997). Influence of monomethylfumarate on monocytic cytokine formation- Explanation for adverse and therapeutic effects in psoriasis? Arch. Dermatol. Res. 289:623-630. (Pubitemid 27510826)
2. Axtell, R. C., de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., De Sarno, P., et al. (2010). T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16:406-412.
3. Bielekova, B. M. R. (2004). Development of biomarkers in multiple sclerosis. Brain 127:1463-1478.
4. Birnbaum, G. (2010) Current and future treatments for relapsing-remitting multiple sclerosis. Curr. Opin. Drug Discov. Devel. 13:214-225.
5. Bovenschen, H. J., Langewouters, A. M., van de Kerkhof, P. C. (2010). Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. Am. J. Clin. Dermatol. 16. [Epub ahead of print]
6. Ehling, R., Berger, T., Reindl, M. (2010). Multiple sclerosis-Established and novel therapeutic approaches. Cent. Nerv. Syst. Agents Med. Chem. 10:3-15.
7. Ghoreschi, K., Rocken, M. (2004). Immune deviation strategies in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy 3:193-198. (Pubitemid 38832750)
8. Goverman, J. (2009) Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9:393-407.
9. Hedegaard, C. J., Krakauer, M., Bendtzen, K., Lund, H., Sellebjerg, F., Nielsen, C.H. (2008). T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125:161-169.
10. de Jong, R., Bezemer, A.C., Zomerdijk, T.P., van de Pouw-Kraan, Ottenhoff, T. H., Nibbering, P. H. (1996). Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 26:2067-2074. (Pubitemid 26297503)
11. Kappos, L., Gold, R., Miller, D. H., Macmanus, D. G., Havrdova, E., Limmroth, V., et al. (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 372:1463-1472.
12. Lee, D. H., Linker, R. A., Gold, R. (2008) Spotlight on fumarates. Int. MS J. 15:12-18.
13. Linker, R. A., Lee, D. H., Stangel, M., Gold, R. (2008). Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother. 8:1683-1690.
14. Litjens, N. H., Rademaker, M., Ravensbergen, B., Rea, D., van der Plas, M. J., Thio, B., et al. (2004). Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur. J. Immunol. 34:565-575. (Pubitemid 39255966)
15. Litjens, N. H., Rademaker, M., Ravensbergen, B., Thio, H. B., van Dissel, J.T., Nibbering, P. H. (2006) Effects of monomethylfumarate on dendritic cell differentiation. Br. J. Dermatol. 154:211-217. (Pubitemid 43382688)
16. Loewe, R., Holnthoner, W., Groger, M., Pillinger, M., Gruber, F., Mechtcheriakova, D., et al. (2002). Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J. Immunol. 168:4781-4787. (Pubitemid 34441387)
17. Lopez-Diego, R. S., Weiner, H. L. (2008). Novel therapeutic strategies for multiple sclerosis-Multifaceted adversary. Nat. Rev. Drug Discov. 7:909-925.
18. Moharregh-Khiabani, D., Linker, R. A., Gold, R., Stangel, M. (2009). Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr. Neuropharmacol. 7:60-64.
19. Mrowietz, U., Christophers, E., Altmeyer, P. (1998) Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br. J. Dermatol. 138:456-460. (Pubitemid 28145514)
20. Ockenfels, H. M., Schultewolter, T., Ockenfels, G., Funk, R., Goos, M. (1998). The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br. J. Dermatol. 139:390-395. (Pubitemid 28430453)
21. Rostami-Yazdi, M., Clement, B., Mrowietz, U. (2010) Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res. 24 [Epub ahead of print]
22. Schilling, S., Goelz, S., Linker, R., Luehder, F., Gold, R. (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin. Exp. Immunol. 145:101-107. (Pubitemid 43893938)
23. Schimrigk, S., Brune, N., Hellwig, K., Lukas, C., Bellenberg, B., Rieks, M., et al. (2006). Oral fumaric acid esters for the treatment of active multiple sclerosis: an openlabel, baseline-controlled pilot study. Eur. J. Neurol. 13:604-610. (Pubitemid 43873632)
24. Yazdi, M. R., Mrowietz, U. (2008). Fumaric acid esters. Clin.Dermatol. 26:522-526.
25. Zhu, K., Mrowietz, U. (2001). Inhibition of dendritic cell differentiation by fumaric acid esters. J. Invest. Dermatol. 116:203-208. (Pubitemid 32173722)